Trials / Enrolling By Invitation
Enrolling By InvitationNCT05495321
Interleukin-2 on Active Dermatomyositis
Therapeutic Effect of Interleukin-2 on Active Dermatomyositis: A Multicenter, Randomised, Double-blind, Placebo-controlled Trial
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
Detailed description
A randomized, double-blind, placebo-controlled, multicenter clinical trial was designed. Patients were treated with low-dose IL-2 regularly to explore its efficacy and safety. The improvement of clinical and laboratory indexes was evaluated. Changes of immune cell subsets and cytokines were monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interleukin-2 | low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months. |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2025-09-01
- Completion
- 2026-09-01
- First posted
- 2022-08-10
- Last updated
- 2022-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05495321. Inclusion in this directory is not an endorsement.